Clinical Cancer Research, Vol 4, Issue 9 2027-2037, Copyright © 1998 by American Association for Cancer Research

ARTICLES

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity

E Frei 3rd, A Elias, C Wheeler, P Richardson and W Hryniuk
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.

The most important variables for the clinical use of antitumor agents (AAs) are dose and combination chemotherapy. The objectives of this study were to analyze the relationship between these two variables and to propose a unified conceptual framework for the construct and interpretation of clinical trials. Definitions and variables with respect to dose include potency, therapeutic index, standard dose, efficacy, relative efficacy, dose-limiting toxicity (DLT), dose rate, dose density, dose intensity, and fractional dose intensity. Our overarching concept, that is, summation dose intensity (SDI), was calculated in several ways, depending upon the nature of the data, and included the relative efficacy method, the unit regimen method, and the high dose method. The SDI concept was then applied to disease categories and strategies to determine its usefulness and effectiveness in integrating dose and combinations. The tumors and settings were: mustargen-vincristine-procarbazine-prednisone in Hodgkin's disease, combination chemotherapy for acute lymphocytic leukemia in children, metastatic breast cancer including dose and combinations, selected other solid tumors, alternating chemotherapy, and high dose studies in the leukemias and lymphomas. SDI was effective in integrating and quantifying dose and combination chemotherapy. For classical AAs, the implication of SDI for the construct and analysis of clinical trials was emphasized. In addition to new drug development, emphasis should be given to reducing or eliminating DLTs, such as those of the marrow, now and, in the future, those of the gastrointestinal tract toxicity and other DLTs. The above was derived from and applies to the classical AAs. Whether they will apply to, with appropriate adjustment, agents with significantly different dose-response curves, such as biotherapeutics and hormonal agents, remains to be determined.

This article has been cited by other articles:

				R. Chun, L. D. Garrett, C. Henry, M. Wall, A. Smith, and N. M. Azene Toxicity and Efficacy of Cisplatin and Doxorubicin Combination Chemotherapy for the Treatment of Canine Osteosarcoma J. Am. Anim. Hosp. Assoc., November 1, 2005; 41(6): 382 - 387. [Abstract] [Full Text] [PDF]

				Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial J. Clin. Oncol., February 1, 2001; 19(3): 602 - 611. [Abstract] [Full Text] [PDF]

				P. J. Woll, N. Thatcher, L. Lomax, J. Hodgetts, S. M. Lee, P. A. Burt, R. Stout, T. Simms, R. Davies, and R. Pettengell Use of Hematopoietic Progenitors in Whole Blood to Support Dose-Dense Chemotherapy: A Randomized Phase II Trial in Small-Cell Lung Cancer Patients J. Clin. Oncol., February 1, 2001; 19(3): 712 - 719. [Abstract] [Full Text] [PDF]

				E. Johnston, J. Crawford, S. Blackwell, T. Bjurstrom, P. Lockbaum, L. Roskos, B.-B. Yang, S. Gardner, M. A. Miller-Messana, D. Shoemaker, et al. Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy J. Clin. Oncol., July 1, 2000; 18(13): 2522 - 2528. [Abstract] [Full Text] [PDF]

				K. A. Keyes, B. Albella, P. M. LoRusso, J. A. Bueren, and R. E. Parchment Cytotoxic Chemotherapy Regimens That Increase Dose per Cycle (Dose Intensity) by Extending Daily Dosing from 5 Consecutive Days to 28 Consecutive Days and Beyond Clin. Cancer Res., June 1, 2000; 6(6): 2474 - 2481. [Abstract] [Full Text]

				B. Fisher, S. Anderson, A. DeCillis, N. Dimitrov, J. N. Atkins, L. Fehrenbacher, P. H. Henry, E. H. Romond, K. S. Lanier, E. Davila, et al. Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25 J. Clin. Oncol., November 1, 1999; 17(11): 3374 - 3388. [Abstract] [Full Text] [PDF]